The global anterior uveitis treatment market is projected to exhibit a significant growth, at a CAGR of around 6.1%, during the forecast period. The increasing prevalence of eye-related disorders has raised the demand for anterior uveitis treatment across the globe. However, a developed region such as North America and Europe hold the highest market share in the anterior uveitis treatment market attributed to the well-developed healthcare industry and the availability of advanced treatment technology. Whereas, in emerging economies such as Latin America, the Middle East and Africa, and some parts of Asia-Pacific, due to lack of awareness and lack of healthcare facilities the market share is quite lesser than other developed economies. There is a large pool of undiagnostic populations with anterior uveitis in this region.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/anterior-uveitis-treatment-market
Growing government initiatives to aware population and provide better healthcare facilities to create enormous opportunities for the anterior uveitis treatment market in the emerging nations. Thus, the major manufacturers of anterior uveitis treatment can enhance their market presence in these economies to strengthen their revenue. Latin American countries such as Brazil and Mexico are also expected to have considerable potential for anterior uveitis treatment market growth during the forecast period. This is due to the increasing healthcare expenditure and growing medical industry. An increasing number of hospitals and ophthalmic clinics in emerging economies are providing immense growth opportunities for the anterior uveitis treatment market.
Cataract is one of the most common complications associated in patients dealing with anterior uveitis. The rising prevalence of cataract-removal surgeries and rising awareness among patients about the advanced technologies in emerging nations is creating ample opportunities for the market players to introduce novel anterior uveitis treatment solutions in this region. Population-based surveys in China have identified cataract as the leading cause of blindness and visual impairment. The Chinese Ministry of Health has reported that 45% of China’s 2,400 country’s hospitals do not offer cataract surgery services and most rural residents are unable to afford surgery in urban centers. On this account various projects were intended, such as Project Vision, a non-governmental organization, to build a sustainable model to reduce cataract blindness in rural China.
According to WHO, approximately 18 million cataract procedures are performed globally every year, which will increase to 24 million soon. As per the International Agency for the prevention of Blindness (IAPB), approximately half the blindness in South Africa is caused due to cataracts. The prevalence of blinding bilateral cataracts in Africa is estimated to be around 0.5%. This increasing prevalence of cataract creates enormous opportunities for the companies developing treatment solutions for the anterior uveitis to expand their market in such emerging economies across the globe.
Global Anterior uveitis treatment Market-Segmentation
By Drug Class
- Corticosteroids
- Anti-inflammatory agents
- Cycloplegics
- Antimetabolites
- Biologics
- Others (Anti-Viral)
A full report of Anterior uveitis treatment Market is available at: https://www.omrglobal.com/industry-reports/anterior-uveitis-treatment-market
